文献速递头颈外科

Beers标准药物对老年头颈癌患者的影响

Impact of Beers Criteria Medications in Elderly Patients With Head and Neck Cancer.
PubMed 文献 · Head Neck · 2026-08-12

本研究基于SEER-Medicare数据回顾性分析5213例≥65岁头颈癌患者,发现Beers标准药物(BCMs)使用呈剂量依赖性降低2年生存率,从无BCMs的88.2%降至≥3种BCMs的81.4%(p<0.001),且BCMs使用者诊断后一年急诊就诊次数更高(平均1.21 vs 0.95,p=0.004)。结论提示需多学科团队进行用药核查以优化预后。

要点

  • 老年头颈癌患者BCMs使用普遍,44%未使用,41.3%使用1种,9.3%使用2种,5.4%使用≥3种。
  • BCMs使用与2年生存率剂量依赖性下降相关(88.2% vs 81.4%,p<0.001)。
  • BCMs使用者诊断后一年急诊利用率更高(平均1.21 vs 0.95 claims,p=0.004)。

核心结论

  • 老年头颈癌患者使用Beers标准药物与较差生存率和增加医疗资源利用相关。
  • 研究强调多学科团队进行用药核查和系统评估的必要性。

研究设计与样本

  • 回顾性研究,使用SEER-Medicare数据,纳入2011至2015年诊断的≥65岁头颈癌患者5213例,平均年龄72.6岁。
  • 主要结局为生存,次要结局为急诊利用率。

主要发现

  • 44%患者诊断后1年内未接受BCMs,41.3%接受1种,9.3%接受2种,5.4%接受≥3种。
  • 最常见处方药物为劳拉西泮(12.3%)、唑吡坦(7.9%)和阿普唑仑(7.5%)。
  • 2年生存率随BCMs使用呈剂量依赖性下降:0种88.2%,1种86.8%,2种86.7%,≥3种81.4%(p<0.001)。
  • BCMs使用者诊断后一年急诊利用率更高(平均1.21 vs 0.95 claims,p=0.004)。

临床怎么用

  • 对老年头颈癌患者应进行用药核查,识别并审慎管理Beers标准药物。
  • 多学科协作优化用药可能改善这一脆弱人群的预后。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Head and neck cancer patients often experience polypharmacy due to complex treatments and comorbidities. The Beers Criteria is a list of potentially inappropriate medications (PIMs) for patients above age 65 developed by the American Geriatrics Society. We hypothesize that increased use of PIMs will be associated with inferior health and quality of life outcomes in elderly patients with head and neck cancer. METHODS: We retrospectively examined patients aged ≥ 65 years with head and neck cancer diagnosed between 2011 and 2015 using SEER-Medicare data, analyzing associations between Beers Criteria Medications (BCMs) and survival as a primary outcome. Emergency department (ED) utilization served as a secondary outcome. RESULTS: Among 5213 patients (mean age 72.6 years), 44% received no BCMs within 1 year of diagnosis, while 41.3% received 1 BCM, 9.3% received 2 BCMs, and 5.4% received ≥ 3 BCMs. The most common medications prescribed were Lorazepam (12.3%), Zolpidem (7.9%), and Alprazolam (7.5%). Two-year survival decreased with BCM use in a dose-dependent fashion: 88.2% (0 BCM), 86.8% (1 BCM), 86.7% (2 BCMs), and 81.4% (≥ 3 BCMs; p < 0.001). BCM users had higher ED utilization in the year after diagnosis (mean 1.21 vs. 0.95 claims, p = 0.004). CONCLUSIONS: BCMs in elderly head and neck cancer patients were associated with inferior survival and increased healthcare utilization. These findings highlight the need for medication reconciliation and systematic reviews by multidisciplinary care teams to optimize outcomes in this vulnerable population.

来源:Head Neck,查看原文。版权归原作者所有。

引用

  1. Lee MY, Sakamoto MM, Kim D, et al. Impact of Beers Criteria Medications in Elderly Patients With Head and Neck Cancer. Head Neck. 2026. PMID: 42590818. doi:10.1002/hed.70429

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。